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Abstract
Objective Examine the health and economic impact of extending screening intervals in people with Type 2 diabetes (T2DM) 
and Type 1 diabetes (T1DM) without diabetes-related retinopathy (DR).
Setting Diabetic Eye Screening Wales (DESW).
Study design Retrospective observational study with cost-utility analysis (CUA) and Decremental Cost-Effectiveness Ratios 
(DCER) study.
Intervention Biennial screening versus usual care (annual screening).
Inputs Anonymised data from DESW were linked to primary care data for people with two prior screening events with no 
DR. Transition probabilities for progression to DR were estimated based on a subset of 26,812 and 1232 people with T2DM 
and T1DM, respectively. DCER above £20,000 per QALY was considered cost-effective.
Results The base case analysis DCER results of £71,243 and £23,446 per QALY for T2DM and T1DM respectively at a 
3.5% discount rate and £56,822 and £14,221 respectively when discounted at 1.5%. Diabetes management represented by 
the mean  HbA1c was 7.5% for those with T2DM and 8.7% for T1DM.
Sensitivity analysis Extending screening to biennial based on  HbA1c, being the strongest predictor of progression of DR, 
at three levels of  HbA1c 6.5%, 8.0% and 9.5% lost one QALY saving the NHS £106,075; £58,653 and £31,626 respectively 
for T2DM and £94,696, £37,646 and £11,089 respectively for T1DM. In addition, extending screening to biennial based on 
the duration of diabetes > 6 years for T2DM per QALY lost, saving the NHS £54,106 and for 6-12 and > 12 years for T1DM 
saving £83,856, £23,446 and £13,340 respectively.
Conclusions Base case and sensitivity analyses indicate biennial screening to be cost-effective for T2DM irrespective of 
 HbA1c and duration of diabetes. However, the uncertainty around the DCER indicates that annual screening should be main-
tained for those with T1DM especially when the  HbA1c exceeds 80 mmol/mol (9.5%) and duration of diabetes is greater 
than 12 years.
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Introduction
In 2019 diabetes was estimated to affect around 463 mil-
lion people globally and is projected to increase to 700 
million in 2045 [1]. Diabetes is a major contributor to 
mortality, morbidity and quality of life with an ever 
increasing impact on health resources [2]. In 2010/2011 
the cost of diabetes to the NHS in the United Kingdom 
(UK) was estimated at £9.6 billion and is expected to rise 
to £16.9 billion by 2035/2036 [3], representing about 10% 
of the NHS budget with approximately 80% consumed in 
treating the complications of diabetes. Diabetes-related 
retinopathy (DR) is a feared complication of diabetes 
capable of causing visual impairment and severe vision 
loss (blindness) with devastating individual and socio-
economic consequences [4–6].
DR, if undiagnosed and remains untreated in its early 
stages, can progress to severe visual loss. The estimated 
cost in the UK in 2010/2011 of treating sight-threatening 
DR was £57 million which is predicted to reach £97 mil-
lion by 2035/2036 [3]. However, screening can detect 
DR well before vision is affected and when treatment is 
most effective to prevent progression and thereby preserve 
vision. To detect DR UK screening utilise digital retinal 
images which are then graded and according to the find-
ings the people are reviewed annually or referred to hospi-
tal eye services for further assessment and treatment. This 
model in addition to possible improvements in diabetes 
management and newer therapies has been demonstrated to 
reduce new certifications for sight impairment and severe 
sight impairment, in Wales by 50% [7]. The proportion of 
sight impairment and severe sight impairment due to DR 
in the UK is expected to decrease from 4.7% in 2013 to 
3.1% in 2050 [6]. The UK model of screening differs to 
that recommended in the US and elsewhere where dilated 
comprehensive eye examination is conducted by an oph-
thalmologist [8]. Although screening for DR has been 
shown to be cost-effective compared to no screening and 
offsets the costs associated with blindness [9–12], the ever 
increasing number of people with diabetes given annual 
screening may soon become financially unsustainable.
In 2016 the UK National Screening Committee also rec-
ommended that screening for DR could be increased from 
annual to biennial in those considered to be at low risk of 
progression to sight-threatening DR—following two con-
secutive negative annual screening events [13–18]. This 
recommendation is based on studies involving people only 
with Type 2 diabetes (T2DM) or mixed populations of 
Type 1 and Type 2 diabetes [13–15, 19]. However, the evi-
dence is limited as to whether extending the screening in 
people with Type 1 diabetes (T1DM) is safe or cost-effec-
tive [20–26]. In 2017, the American Diabetes Association 
(ADA) also recommended screening be conducted every 
2 years conditional on there being no evidence of DR on 
one or more prior annual screening events, with glycaemia 
well managed and with robust information technology sys-
tems and support to ensure future re-call for screening [8].
The aim of the analysis reported here is to estimate 
the likely economic consequences of extending screening 
intervals from annual to biennial in people considered to 
be at low risk for developing sight-threatening DR with 
either T1DM or T2DM. The analyses used routine clini-
cal data taking into account type of diabetes, blood pres-
sure (BP) and total cholesterol, and the difference in the 
rate of progression to DR. This will provide evidence on 
which regulatory authorities such as the National Institute 
of Clinical Excellence (NICE) and the National Screen-
ing Committee (NSC) in the UK, to base their future DR 
screening guidelines.
Populations and methods
Population and setting
People with either T1DM or T2DM (total 91,393; T1DM 
5003; T2DM 86,390) undergoing screening for DR in a 
systematic community-based programme in Wales, UK 
between 2005 and 2009. Those included in the study had 
no evidence of DR at the first screening and had at least one 
further screening event [27].
Data from the Diabetic Eye Screening Wales (DESW) for 
all persons with diabetes ≥ 12 years registered with a GP in 
Wales, which included age, gender, date of diagnosis, type 
and treatment of diabetes, date of screening, DR grade and 
visual acuity [12] were transferred to the National Health 
Service (NHS) Wales Informatics Service for anonymisa-
tion and given a unique linking field number [28]. The data 
were then transferred to the Secure Anonymised Informa-
tion Linkage (SAIL) databank [29] where it was linked with 
the Welsh Longitudinal General Practice (WLGP) dataset 
[30] which contained information on  HbA1c, BP, cholesterol 
level, treatment for hypertension and dyslipidaemia, diabetes 
treatment, and smoking status. The WLGP dataset contains 
data from approximately 80% of primary care practices in 
Wales. The combination of the DESW and WLGP datasets, 
along with the requirement of at least 2 screening events 
(the first of which had no evidence of DR) with clinical 
information available within the WLGP database and with 
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a confirmed specific diagnosis of T1DM or T2DM (and 
not ‘diabetes’), limited the population size available for the 
analysis. Therefore, the number of people included in the 
combined, final datasets available for analysis to 1232 peo-
ple with T1DM and 26,812 people with T2DM.
Transition probabilities
Information was sourced from the literature on transition 
probabilities for the different levels of DR whilst under the 
care of hospital eye services (Supplementary Table 1), treat-
ment and service costs within hospital eye services (Table 1), 
cost of blindness (Table 1) and quality of life (Table 2). 
Transition probabilities for sight-threatening DR could not 
be calculated from DESW data as people are referred to 
hospital eye services (HES) once a sight-threatening level of 
DR is reached and they do not re-enter screening until treat-
ment has stabilised, therefore, the progression of DR during 
monitoring and treatment within HES was unavailable for 
this population. To derive the transition probabilities for the 
CUA the time to an event of sight-threatening DR was mod-
elled although the exact time the sight-threatening DR devel-
oped was unknown because it will have occurred between 2 
screening events. Therefore, the data was interval censored, 
as well as right censored for those where sight-threatening 
DR did not occur by the last time they were screened but 
may occur in the future. Due to the interval censoring a 
Cox proportional hazards model could not be used, therefore 
parametric models were considered. Weibull, Gompertz and 
lognormal models were fitted to the data and the Akaike 
information criterion (AIC) method used to determine the 
best fit. Weibull modelling was used to estimate the prob-
ability of an event of sight-threatening DR occurring for 
each person, based on their clinical history in the form of a 
survival function S(t), that is the probability that the retin-
opathy event has not occurred by time (t). This has survival 
and hazard functions of the form
Weibull regression analysis was implemented by the 
routine INTCENS programme in STATA. Risk factors for 
the progression of DR were added to the Weibull model 
in a stepwise manor with those not statistically significant 
removed. The final Weibull model used to generate transi-
tion probabilities for moving from one severity level of DR 
to another including the risk factors  HbA1c, BP, cholesterol 
level, treatment of hypertension and dyslipidaemia, diabetes 
treatment and smoking status (Supplementary Table 2).
The transition probabilities derived from the survival 
analysis were then used to populate a de-novo multi-level 
Markov model to estimate the impact of extending screening 
beyond annual and the consequences at different  HbA1c lev-
els were estimated. The model structure and flow of people 
S(t) = exp(−tp), h(t) = ptp−1
Table 1  Resources used in 
screening and treatment of DR
Procedure/condition Cost
Screening visit in DR screening service in Wales £33 [25]
Hospital-based DR screening visit £106 [33]
Optical Coherence Tomography (per scan) £117 [33]
Focal Laser/panretinal photocoagulation laser £131 [33]
Anti-VEGF treatment for maculopathy (drug + administration costs) £822 (£742 + £80) [33]
Vitrectomy £989 [33]
Sight loss (person remains living at home) per annum £1483 [33]
Sight loss (person resident in care home) per annum £6972 [33]
Table 2  RDR utility values 
taken from Lund et al. [30]
RDR state EQ-5D values [30]
Pre proliferative 0.7915
Maculopathy 0.7365
Pre proliferative and maculopathy 0.7365
Easy to treat proliferative 0.7047
Easy to treat proliferative and maculopathy 0.693
High risk proliferative 0.7047
High risk proliferative and maculopathy with visual impairment 0.693
Severe proliferative 0.7047
Severe proliferative with maculopathy and vision loss 0.693
Severe loss of vision 0.6218
 R. L. Thomas et al.
1 3
are represented in Fig. 1. Life tables were used in the analy-
sis. Life table data for the general population obtained from 
the Office of National Statistics (ONS) was used with adjust-
ments made to reflect the increased mortality risk associated 
with T1DM or T2DM.
Model inputs
DR in Wales is graded according to the enriched version 
of the English DR grading protocol [27, 31] where No DR 
means no lesions of DR are visible on the retina; minimum 
Background DR (BDR) where microaneurysms, haemor-
rhages and exudates (not within 1 disc diameter of the fovea) 
can all be present but do not meet the criteria for Moder-
ate BDR; Moderate BDR where microaneurysms, < 8 blot 
haemorrhages and exudates (not within 1 disc diameter of 
the fovea) are present and Referable DR (RDR) consisting 
of Pre-proliferative DR (PPDR) where > 8 blot haemor-
rhages, intra-retinal microvascular anomalies (IRMA) and 
venous beading are present, Proliferative DR (PDR) where 
new vessels on the optic disc and/or elsewhere, pre-retinal 
haemorrhages, vitreous haemorrhages, retinal detachment 
and fibrosis are present and exudative maculopathy.
As the primary care dataset obtained from SAIL was 
related to GP appointments and not screening events, mod-
elling methods were employed to enable estimation of the 
clinical values  (HbA1C, systolic and diastolic BP, serum 
cholesterol, high and low-density lipids, triglycerides, GFR, 
body mass index (BMI)] which were combined into body 
mass index [BMI] at the time of DR screening. Multilevel 
modelling was used for the longitudinal data using a quad-
ratic function of time for the correlation between different 
measurements from the same subject but constrained to fol-
low a normal distribution across subjects. These coefficients 
were combined with the times of screening allowing predic-
tion of the values at each screening event.
For the economic analysis the population and distribution 
of people with diabetes undergoing screening in Wales in 
2005–2009, i.e. 5003 people with T1DM and 86,390 people 
with T2DM—were used to populate the model [27]. The 
economic analyses estimated the rate of progression from no 
disease to different stages of DR and the dynamic transition 
probabilities from the estimates of progression were incor-
porated into the model (supplementary Tables 3a and 3b).
Comparators and time horizon
The impact of extending the screening interval to biennial 
was compared against usual care which is annual screening 
for both people with T1DM and T2DM. The analysis was 
conducted with a lifetime time horizon enabling estimation 
of the long-term impact on DR and its management resulting 
from changes to the screening schedule.
Discount rate
As some of the observed DESW screening intervals exceed 
the target of an annual review at exactly 12 months, the 
future costs and benefits beyond 12 months were discounted 
back to present day values in line with the NICE reference 
case at a standard rate (currently 3.5% with sensitivity analy-
sis at 1.5%) [32].
Fig. 1  The Markov model 
structure
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Economic evaluation methods
To assess the relative cost effectiveness of extending screen-
ing intervals from annual to biennial a cost-utility analysis 
(CUA) was used. A Markov model was utilised to facilitate 
the CUA with a cycle length of 6 months. The impact on 
health-related quality of life (HRQoL) quantified as health 
utilities according to the health status characterising DR in 
its later stages as described by Royle and colleagues in their 
study were used [33].
Outcomes
Quality-adjusted life years (QALYs) were the outcome 
measure used to calculate the difference in cost between 
screening interval options, divided by the difference in their 
effect. The decremental cost-effectiveness ratio (DCER), an 
approach used in a situation where the analysis of a health 
strategy appears to reduce healthcare expenditure by remov-
ing or substituting an intervention, was also calculated (sup-
plementary Fig. 1). The decision rule is that a strategy is 
considered cost-effective if the incremental cost-effective-
ness ratio (ICER) is below a threshold of £20,000 per QALY, 
as used by the National Institute of Health and Care Excel-
lence (NICE) in England and Wales. The reverse is true for 
a DCER, with values above the threshold of £20,000 per 
QALY considered cost-effective.
Resources and costs
An NHS and personal social services (PSS) perspective was 
adopted and the model was designed to estimate healthcare 
resource use and cost of sight-threatening DR treatment and 
management.
Currency, price, date and conversion
A price year of 2018 was used in the analysis and costs were 
reported in pound sterling (£). A number of sources were 
used to identify the relevant UK NHS resources and related 
costs associated with DR screening, treatment and manage-
ment of different stages of DR (Table 1).
Assumptions
Analysis of our data revealed the progression of DR to be 
a dynamic process, i.e. the development of RDR acceler-
ates with increasing severity of DR. To ensure the model 
also reflected usual practice within DESW, the model path-
way was divided into four DR states i.e. No DR, Minimum 
BDR, Moderate BDR, and RDR. People entered the model 
at the time of the first screening event. Those who entered 
the RDR state within the first year of the 2-yearly screening 
interval were assumed (based on clinical advice) to progress 
without treatment during the following year. People who 
stayed within the RDR state were characterised by PDR and 
maculopathy.
The impact of a delay in the identification of people with 
RDR, because of longer screening intervals, is driven pri-
marily by the severity of DR diagnosed at the first visit to 
the hospital eye service (HES) following referral from the 
screening service. The prevalence for people attending HES 
was calculated by progressing the current RDR distribu-
tion [27], in combination with the transition probabilities 
reported by Royle et al. [25].
On referral to HES, the RDR pathway followed in Wales 
incorporated ten clinically relevant health states with differ-
ing severity levels of DR and maculopathy. The assumptions 
made about treatment for those within the RDR category 
in HES can be seen in Supplementary Tables 4a and 4b 
[30]. The use of surrogate markers for maculopathy based 
on non-stereoscopic digital photography may result in over 
referral to HES for further assessment with a proportion dis-
charged after the first HES appointment back to DESW. To 
account for this and simulate the known occurrence of false 
positives from the DESW screening reports and subsequent 
referrals to HES which prove negative, a linear reduction of 
one severity step within the RDR states was implemented at 
a rate of 50%, this adjustment was made to reflect an appro-
priate ‘knockback’ effect [27].
The RDR distribution was progressed through the model 
for one year to simulate the unidentified progression of DR 
(Supplementary Table 5) and related health service treat-
ment costs and the decrement in health utility. The resulting 
value was adjusted to represent the average difference in cost 
and health utilities for a single patient within a six-month 
period. The combination of STDR and maculopathy and the 
occurrence of screening within the RDR pathway meant that 
patients often remained untreated for one or both conditions 
and were assumed to follow the same transition progres-
sion as before. People, who received treatment for STDR 
or maculopathy, were assumed to be ‘stationary’ within the 
model, thereafter.
Sensitivity analysis
To explore the effect of uncertainty on the outcomes of our 
analyses we conducted both deterministic and probabilistic 
sensitivity analysis.
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Results
Study parameters
People with T1DM without DR at first screening event 
were younger (22.7 years) with a longer duration of diabe-
tes (7.8 years) and a higher  HbA1c [71.6 mmol/mol (8.7%)] 
compared to those with T2DM without DR [age 62.3 years, 
known duration of diabetes 4.2 years,  HbA1c 58.5 mmol/mol 
(7.5%)] (Table 3). All people with T1DM were treated with 
insulin, with 1.6% receiving metformin and surprisingly 
9.8% were recorded as being prescribed sulphonylureas in 
addition to their insulin which casts doubt on the accuracy 
of the designated type of diabetes recorded. However, in the 
absence of being able to review the clinical data due to the 
anonymisation procedure no change was made to the data-
base, but this limitation was noted.
Transition through the stages of DR to RDR occurred 
faster for people with T1DM compared to those with T2DM. 
The risk of progression analysis indicates that  HbA1c and 
duration of diabetes were the strongest predictors of progres-
sion of DR. The transition probabilities were highly sensitive 
to the threshold level of  HbA1c for both T1DM and T2DM, 
with higher levels resulting in an increased rate of DR pro-
gression. Supplementary Figs. 2a, 2b, 3a and 3b illustrate 
the time to the development of RDR for T1DM and T2DM 
at different levels of  HbA1c and known duration of diabetes. 
The median time to the development of RDR occurred at 
20 years for  HbA1c of 47.5 mmol/mol (6.5%), 13 years at 
63.9 mmol/mol (8.0%) and 8 years 74.9 mmol/mol (9.0%) 
respectively for T1DM and > 20 years, 17 years and 12 years 
respectively for T2DM. For people with T1DM there was a 
distinctly slower rate of progression to RDR for those with 
a shorter duration of diabetes (< 6 years) versus those with a 
longer duration (≥ 6 years) with little difference in the speed 
of progression between 6–12 and > 12 years duration. For 
people with T2DM the speed of progression to RDR was 
quickest in people with diabetes for > 6 years, intermediate 
for 3-6 years and slowest for < 3 years duration. The median 
time to development of RDR for T1DM was < 20 years 
after < 6 years of diabetes, and 10 years after ≥ 6 years of 
diabetes. In comparison, the median time to development 
of RDR in T2DM was > 20 years with a known duration of 
diabetes of < 3 years, 19 years after 3–6 years and > 15 years 
after a known duration of diabetes of > 6 years.
Incremental costs and outcomes
The base case results of the analysis showed that extending 
the screening interval in people with T1DM and T2DM to 
biennial reduced costs by £37 and £79 per person, respec-
tively and effectiveness by 0.0016 and 0.0011 QALYs 
Table 3  Demographics of the DESW population 2003–2013 included 
in the statistical analysis to estimate the transition probabilities
T1DM (1232) T2DM (26,812)
Age mean (SD) 22.7 (11.6) 62.3 (12.1)
Gender: male % 53.8 56.1
Known duration of diabetes mean 
(SD)
7.8 (9.4) 4.2 (4.1)
HbA1c (mmol/mol) mean 71.6 58.5
HbA1c (%) mean (SD) 8.7 (1.6) 7.5 (1.2)
Treatment of diabetes %
Metformin (as one treatment) 1.6 60.5
Sulphonylurea (as one treatment) 9.8 22.0
Insulin alone 88.5 4.1
Systolic BP mean (SD) 121.7 (9.5) 138.2 (10.6)
Diastolic BP mean (SD) 71.8 (5.6) 79.2 (6.3)
Total cholesterol 4.5 (0.7) 4.6 (0.8)
HDL-cholesterol 1.5 (0.4) 1.2 (0.3)
LDL-cholesterol 2.5 (0.6) 2.4 (0.7)
Triglycerides 1.3 (0.6) 2.1 (1.0)
eGFR 107.9 (22.8) 79.5 (18.7)
BMI mean (SD) 24.1 (4.6) 32.3 (6.3)
Smokers: yes % 3.8 38.7
Table 4  Estimated DCERs for increasing annual screening to biennial screening by  HbA1c level and duration of diabetes
a Mean  HbA1c value for the population with T1DM
b Mean  HbA1c value for the population with T2DM
c Changing to biennial screening ICER considered cost effective at above £20,000 per QALY lost threshold
HbA1c level mmol/mol (%) Duration of diabetes (years)
48 (6.5) 64 (8.0) 72 (8.7)a 80 (9.5) < 6 6–12 > 12
T1DM (DCER QALY £) 94,696c 37,646c 23,446c 11,089 83,856c 23,446 13,340
HbA1c level mmol/mol (%) Duration of diabetes (years)
48 (6.5) 58.8 (7.5)b 64 (8.0) 80 (9.5) < 3 3–6 > 6
T2DM (DCER QALY £) 106,075c 71,243c 58,653c 31,626c 87,405c 71,243c 54,106c
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respectively. The resulting DCERs of £23,446 and £71,243 
per QALY for T1DM and T2DM, respectively are above the 
threshold of £20,000 per QALY indicating that the biennial 
screening strategy is cost-effective in both populations.
Sensitivity analysis
Deterministic sensitivity analysis was conducted for a num-
ber of scenarios using the strongest predictors of progres-
sion to RDR i.e.  HbA1c and known duration of diabetes 
(Table 4). For people with T1DM at Analysis 2:  HbA1c lev-
els of 48 mmol/mol (6.5%) the DCER was £94,696 (analy-
sis 1) falling to £37,646 at 64 mmol/mol [8.0% (analysis 
2)], to £23,446 at 72 mmol/mol [8.7% (analysis 3)] and 
finally to £11,089 at 80 mmol/mol [9.5% (analysis 4)]. 
When the duration of diabetes was varied those with T1DM 
for < 6 years had a DCER of £83,856 (analysis 5) which 
reduced to £23,446 after 6-12 years (analysis 6) and £13,340 
after 12 years (analysis 7). These analyses, at a threshold of 
£20,000, suggest that for those people with T1DM for less 
than 6 years it would be considered cost-effective to extend 
the screening interval to biennial (analysis 5), becoming bor-
derline cost-effective between 6 and 12 years (analysis 6) 
and not cost-effective after 12 years (analysis 7) nor would 
it be cost-effective at a  HbA1c level between of 80 mmol/
mol (9.5% [analysis 4]) or above. In contrast for those people 
with T2DM extending the screening interval to biennial for 
all analysis performed the DCER remained cost effective at 
a threshold of > £20,000 for all modelled  HbA1c levels and 
diabetes durations.
Additional sensitivity analysis was performed where the 
discount rate for costs and outcomes was reduced to 1.5%. 
This reduction reduced the DCER for biennial screening 
intervals to £14,221 per QALY lost for T1DM and £56,822 
per QALY lost for T2DM.
Probabilistic sensitivity analysis was conducted to assess 
the combined parameter uncertainty in the model. In this 
analysis, the mean values that were utilised in the base-case 
were replaced with values drawn from distributions around 
the mean values. At a threshold of > £20,000 per QALY 
gained, extending the screening interval to biennial was 
found to have a 57% and 97% probability of being cost-
effective in people with T1DM and T2DM, respectively.
Discussion
Our analysis suggests that for the base case at the discount 
rate of 3.5% extending the screening interval from annual to 
biennial for people with T2DM and T1DM without evidence 
of DR at first screening exceeded the threshold for cost-
effectiveness at £71,243 and £23,446 respectively. There-
fore, increasing the screening interval achieves a substantial 
resource saving with only a very small impact on the out-
comes. However, if the discounted rate was reduced to 1.5% 
increasing the screening interval remained cost-effective for 
those with T2DM at £56,822, but not for those with T1DM 
at £14,221 for whom screening should continue annually.
As glycaemic control  (HbA1c) and duration of diabetes 
are known key risk factors for the onset and progression 
of diabetic retinopathy they were therefore included in a 
sensitivity analysis at the 3.5% discount rate. In those with 
T2DM the  HbA1c levels and duration of diabetes did not 
reduce the cost-effectiveness when extending the screening 
interval from annual to biennial. However, for those with 
T1DM extending the screening interval beyond annual was 
only cost-effective when the  HbA1c was below 64 mmol/mol 
(8.0%) and was only borderline cost effective at 72 mmol/
mol (8.7%) and clearly not cost effective at 80 mmol/mol 
(9.5%) or higher. Also extending the screening intervals 
was only cost-effective when the duration of T1DM was 
≤ 12 years.
Probabilistic sensitivity analysis demonstrated that the 
degree of uncertainty around the result was very different 
in people with T2DM and T1DM. There was relatively 
little uncertainty around the result in T2DM with a 97% 
probability, suggesting that the recommendation of extend-
ing the screening interval to biennial would very likely be 
cost-effective. Conversely, there was a high degree of uncer-
tainty around the result in T1DM with a 57% probability that 
extending the screening interval to biennial would be cost-
effective and, therefore, not a strategy to be recommended 
for any T1DM population based on our findings.
It is important to note that the outcomes of our analyses 
are based on a ‘perfect health system’ where all screening 
resources and costs that are recoverable can be deployed 
elsewhere and screening uptake is assumed to be 100%. 
Important potentially quantifiable factors not available to 
include in this analysis, since they are setting specific, are 
the extent of the estimated resource and cost savings recov-
erable from increasing screening intervals if the increase 
in screening intervals were implemented for the groups of 
people identified in this analysis. Also influential are the 
ascertainment rates of the population to be included in the 
screening programme [34], as well as uptake rates for the 
screening programme which in Wales is currently 80% 
[35]. These factors are likely to reduce the borderline cost-
effectiveness, based at the 3.5% discount rate, for T1DM 
as well as those in the sensitivity analysis at  HbA1c level of 
72 mmol/mol (8.7%) and 6–12 years duration of diabetes to 
below the threshold of greater than £20,000 considered to 
be cost-effective by NICE.
An important driver of outcomes in the model is the 
increased risk of progression to RDR, which influences 
the outcome for the person with DR if there is a delay in 
treatment due to screening interval increases. The speed of 
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transition and missed treatment opportunities for people with 
RDR consequently increases the number of people requiring 
treatment, thus increasing health care resource use and costs. 
Another issue for outcomes is that over the time horizon of 
the model people with T1DM experience a higher mortality 
rate than those with T2DM [24]. On the other hand, people 
with T2DM are older at the onset of their diabetes, have 
a shorter exposure to diabetes but are more likely to die 
within the time horizon of our model as a result of a shorter 
remaining lifespan.
Previous studies that have assessed the cost effectiveness 
of extending screening intervals have either focussed solely 
on people with T2DM [22, 23] or have combined people 
with T1DM and T2DM into one group [10, 25] and found 
that increasing screening intervals to 2-5 years to be safe and 
cost effective in those at low risk of progression to sight-
threatening DR. The DCCT/EDIC study group did look 
exclusively at people with T1DM [33] however this popula-
tion was from a Randomised Control Trial and so generalis-
ability to real-world populations is limited. This was based 
on a 4 year, 3 year, 6 month and 3 month screening schedule 
for those participants of the DCCT/EDIC trial categorised 
into low to high-risk groups resulting in a 58% reduction in 
screening appointments per patient versus annual screen-
ing and projected to save approximately $1 billion over a 
20 year period. Eleuteri et al. developed a risk calculation 
engine (RCE) to assign personalised screening intervals and 
found that individualised intervals of 6, 12 and 24 months 
with a 2.5% risk threshold using the RCE method was fea-
sible, reliable, safe and acceptable to people with diabetes 
whilst reducing the number of screening episodes by 30% 
[36]. Although the RCE used covariates such as duration of 
diabetes,  HbA1c, BP and total cholesterol but unfortunately 
the type of diabetes was not included and no adjustment 
was made for the difference in the rate of progression of DR 
between T1DM and T2DM.
Wales has a higher prevalence of diabetes than the 
remainder of the UK [37]. Also screening models differ 
slightly in that England employs a mixture of programmes 
using optometrists or screener graders and Scotland predom-
inantly rely on only one retinal image per eye. However, 
these findings should still be applicable where systematic 
screening programme exist with central call/recall facilities 
with the possible exception of those regions or countries 
with higher proportions of ethnic minorities which have a 
higher risk of diabetes and progression of complications 
[38].
We acknowledge that there are limitations to this study 
related to the data recorded by DESW when people with 
diabetes first appear for their first screening event following 
a referral from general practice. Data cleaning procedures 
were employed to ensure the accuracy of the diagnosis of 
diabetes, despite which a proportion of people classified as 
T1DM were reported to be treated both with insulin and 
with metformin (1.6%) and/or sulphonylureas (9.8%) which 
indicate that this small cohort of participants could well be 
miss-classified, but this could not be confirmed due to the 
anonymisation procedure. This potential ‘contamination’ is 
unlikely to have affected the results for people with T1DM 
such that our recommendations would change. In addition, 
the exclusion of comorbidities could also be a limitation.
The modelling methods used to estimate the impact of 
changing the screening interval include uncertainty inher-
ent in the evidence informing the model, such as the natu-
ral history of DR progression and the association between 
health utility scores and visual acuity and the impact on 
costs and outcomes of the various treatments. We were 
unable to source from the local service data some transition 
probabilities for variables e.g. those related to HES, treat-
ment effectiveness, health utility scores and the economic 
consequences of visual loss which were therefore obtained 
from the literature. As a result, albeit that these transition 
probabilities were derived from UK data, the populations 
on which these studies were based mean that their results 
might be different from that which the majority of our data 
were obtained.
The strength of this study is that it is the first large com-
munity based nationally representative dataset that links 
person-level data on DR screening and risk factors for the 
progression of DR. Importantly the addition of clinical diag-
noses and risk factors to the dataset allowed analysis to be 
conducted separately for T1DM and T2DM. There have been 
very few studies to date of the cost-effectiveness of extend-
ing the screening interval particularly in people with T1DM 
alone.
Our analyses, reported here, identified a distinct differ-
ence in relative cost effectiveness at different thresholds of 
 HbA1c and duration of diabetes, driven by the underlying 
risk of progression to RDR between people with T2DM 
and T1DM. This means that extending screening intervals 
to biennial in people with T2DM is most likely to be cost 
effective according to current NICE guidelines which would 
allow policy makers to re-deploy the gains elsewhere. How-
ever, extending screening intervals beyond annual for people 
with T1DM appears only to be clearly cost effective when 
 HbA1c level is < 64 mmol/mol (< 8.0%), and duration of dia-
betes < 6 years. Extending the screening interval in persons 
with T1DM beyond annual should not be introduced where 
 HbA1c is above 80 mmol/mol (9.5%) and the duration of 
diabetes is greater than 12 years.
Ultimately screening programmes should adopt the prin-
ciples of precision medicine requiring further research to 
arrive at an algorithm that can individualise screening inter-
vals of based on the current status of the retinal vasculature 
and the presence of putative risk factors thereby optimising 
Cost‑effectiveness of biennial screening for diabetes related retinopathy in people with…
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the use of resources without increasing the risk of vision 
loss and blindness.
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